Payment overview · 2025
General Payments
$244.33
13 reported records · 9 companies
Healthcare provider profile · identity verified
David A Abbott, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND HEIGHTS, MO · NPI 1568448850
Verified facts
What the public records show
CMS Open Payments records show David A Abbott, MD received $244.33 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Rybelsus.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 486 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.13 | 23.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.36 | 17.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.71 | 15.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.14 | 9.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.07 | 7.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.46 | 7.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.59 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.20 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.67 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.33 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
486 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1276 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 966 | 123 |
| Furosemide | Furosemide | 961 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 851 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 600 | 71 |
| Lisinopril | Lisinopril | 547 | 60 |
| Potassium Chloride | Potassium Chloride | 541 | 55 |
| Gabapentin | Gabapentin | 508 | 48 |
| Eliquis | Apixaban | 486 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 474 | 49 |
| Donepezil Hcl | Donepezil Hcl | 453 | 38 |
| Losartan Potassium | Losartan Potassium | 438 | 60 |
| Sertraline Hcl | Sertraline Hcl | 415 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 414 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 396 | 29 |
| Trazodone Hcl | Trazodone Hcl | 376 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 46 |
| Omeprazole | Omeprazole | 363 | 56 |
| Tramadol Hcl | Tramadol Hcl | 287 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 281 | 34 |
| Memantine Hcl | Memantine Hcl | 273 | 27 |
| Mirtazapine | Mirtazapine | 267 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 225 | 12 |
| Metformin Hcl | Metformin Hcl | 214 | 41 |
| Levetiracetam | Levetiracetam | 202 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 36 |
| Buspirone Hcl | Buspirone Hcl | 190 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 190 | 21 |
| Simvastatin | Simvastatin | 178 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 19 |
| Prednisone | Prednisone | 163 | 24 |
| Famotidine | Famotidine | 159 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 153 | 12 |
| Carvedilol | Carvedilol | 142 | 24 |
| Gemtesa | Vibegron | 135 | suppressed |
| Lorazepam | Lorazepam | 134 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 133 | 11 |
| Metolazone | Metolazone | 132 | 24 |
| Digoxin | Digoxin | 131 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 129 | 17 |
| Allopurinol | Allopurinol | 126 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 18 |
| Glimepiride | Glimepiride | 120 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 21 |
| Finasteride | Finasteride | 118 | 18 |
| Lovastatin | Lovastatin | 114 | 12 |
| Celecoxib | Celecoxib | 111 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 13 |
| Alprazolam | Alprazolam | 100 | 18 |
| Meloxicam | Meloxicam | 100 | 16 |
| Warfarin Sodium | Warfarin Sodium | 98 | 11 |
| Myrbetriq | Mirabegron | 97 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 14 |
| Cephalexin | Cephalexin | 86 | 44 |
| Primidone | Primidone | 85 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 17 |
| Alendronate Sodium | Alendronate Sodium | 80 | suppressed |
| Spironolactone | Spironolactone | 78 | 15 |
| Temazepam | Temazepam | 78 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 52 |
| Clonazepam | Clonazepam | 76 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 75 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 14 |
| Midodrine Hcl | Midodrine Hcl | 72 | suppressed |
| Glipizide | Glipizide | 71 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 70 | suppressed |
| Jardiance | Empagliflozin | 69 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 63 | suppressed |
| Nystatin | Nystatin | 63 | 29 |
| Ramipril | Ramipril | 62 | suppressed |
| Loperamide | Loperamide Hcl | 60 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 12 |
| Latanoprost | Latanoprost | 58 | 14 |
| Lansoprazole | Lansoprazole | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 30 |
| Jantoven | Warfarin Sodium | 53 | suppressed |
| Leflunomide | Leflunomide | 53 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 52 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 51 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 51 | suppressed |
| Irbesartan | Irbesartan | 50 | suppressed |
| Torsemide | Torsemide | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 47 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 17 |
| Folic Acid | Folic Acid | 42 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 24 |
| Phenytek | Phenytoin Sodium Extended | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 27 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Klor-Con M10 | Potassium Chloride | 28 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 27 | suppressed |
| Felodipine Er | Felodipine | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Anastrozole | Anastrozole | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 24 | suppressed |
| Restasis | Cyclosporine | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 12 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Colchicine | Colchicine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Clonidine | Clonidine | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.33 · 13 records | Novo Nordisk Inc | Cologuard Collection Kit, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, Wegovy, ZENPEP, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error